Page 179 - 2026 SMOG

Y-SITE AND SOLUTION COMPATIBILITY
Purpose
The following contains the compatibility information presented on the following two charts:
• Y-site Compatibility: A single drug that is administered simultaneously at a Y-site connection
with another drug in a solution
• Solution Compatibility: A single drug in a solution
Note: The resource utilized can provide additional information containing the specific studies
noted in the Incompatible or Uncertain categories. It can also perform additional drug mixture
compatibility (ex, admixture and syringe compatibility).
Compatible No change in visible or electronically determined particulates, haziness or
“C” turbidity, frank precipitation, color, or evolution of a gas.
All drug components in the test samples were found to be chemically stable
(<10% loss of intact drug) for at least 24 hours under the conditions being tested.
All drug components in the test samples were found to be chemically stable
(<10% loss of intact drug) for the entire period of the study under the conditions
being tested, even if the study period was <24 hours.
Incompatible A change in visible or electronically viewed (even if not visible) particulates;
“N” haziness or turbidity, frank precipitation, or color or gas evolution occurred
One or more drug components in the test samples exhibited a loss of intact drug
>10% within 24 hours under the conditions being tested.
Uncertain For research results that do not fit these conventional guidelines, the research
“U” results are designated as Uncertain or Variable. Apply judgment in using these
results. Examples include:
• A transient precipitation formed upon mixing but then disappeared. The
precipitate may or may not show up again later.
• Among repeat test samples, microparticulate formation was electronically
determined to have formed in some samples but not others.
• The test drug in a solution was stable in one container type but not another or
with some drug delivery devices but not others.
• Compatibility of a drug(s) is dependent on the manufacturer(s) of the products
and/or the use of specific product formulations.
• When both compatible and incompatible study results are available for the
same drug pair. Many of these may be due to differences in concentrations of
either drug or in the solution diluent.
• Any other research result that does not fit the conventional guidelines of
compatibility or incompatibility
No data
“NA” No data for administration methods chosen
N/A
“/” Not applicable
™
™
®
Reference: UpToDate Lexidrug Trissel’s 2 IV Compatibility

2026 Standard Medical Operating Guidelines (SMOG) • 171